Vor Biopharma (VOR) Accumulated Expenses (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Accumulated Expenses data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 21.18% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 21.18% increase from a year earlier, with the FY2025 full-year figure at $19.8 million, up 53.3% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.2 million, down from $19.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for VOR reached as high as $58.1 million in Q2 2025 and fell as low as $1.6 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $10.4 million across 5 years, with a median of $7.3 million in 2023.
• Across the five-year window, Accumulated Expenses tumbled 82.98% in 2023 and surged 658.93% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $7.9 million in 2022, then jumped by 37.88% to $10.9 million in 2023, then advanced by 18.53% to $12.9 million in 2024, then surged by 53.3% to $19.8 million in 2025, then tumbled by 88.74% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $2.2 million in Q1 2026, $19.8 million in Q4 2025, and $17.7 million in Q3 2025.